Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear

First Line ◽

First Line Therapy ◽

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

ESMO Open ◽

10.1016/j.esmoop.2021.100062 ◽

2021 ◽

Vol 6 (2) ◽

pp. 100062

Author(s):

J. Sastre ◽

P. García-Alfonso ◽

J.M. Viéitez ◽

M.T. Cano ◽

F. Rivera ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Phase Ii ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Wild Type ◽

First Line ◽

Pik3ca Mutations ◽

First Line Therapy ◽

Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG

Annals of Oncology ◽

10.1093/annonc/mdz246.053 ◽

2019 ◽

Vol 30 ◽

pp. v218

Author(s):

S.W. Sahm ◽

M.-O. Zahn ◽

C. Maintz ◽

T. Goehler ◽

J. Janssen ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Subgroup Analysis ◽

First Line ◽

Interventional Study ◽

First Line Therapy ◽

Line Therapy ◽

Systemic Antibiotics

Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma

Cancer ◽

10.1002/cncr.21411 ◽

2005 ◽

Vol 104 (9) ◽

pp. 1871-1884 ◽

Cited By ~ 28

Author(s):

Bruce E. Hillner ◽

Deborah Schrag ◽

Daniel J. Sargent ◽

Charles S. Fuchs ◽

Richard M. Goldberg

Keyword(s):

Cost Effectiveness ◽

Colorectal Carcinoma ◽

First Line ◽

First Line Therapy ◽

Impact of surgical resection of liver metastases on outcome of patients with KRAS-wildtype exon 2 (KRAS-wt) metastatic colorectal carcinoma (mCRC) treated with a cetuximab-based first-line therapy - Interim analysis of the German non-interventional study ERBITAG

Annals of Oncology ◽

10.1093/annonc/mdw370.39 ◽

2016 ◽

Vol 27 ◽

pp. vi162

Author(s):

U. Neumann ◽

T. Goehler ◽

C. Hering-Schubert ◽

J. Janssen ◽

S. Sahm ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Liver Metastases ◽

Surgical Resection ◽

Interim Analysis ◽

First Line ◽

Interventional Study ◽

Exon 2 ◽

First Line Therapy ◽

O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

Annals of Oncology ◽

10.1093/annonc/mdv235.19 ◽

2015 ◽

Vol 26 ◽

pp. iv115 ◽

Cited By ~ 3

Author(s):

R. Garcia-Carbonero ◽

R. Obermannova ◽

G. Bodoky ◽

J. Prausova ◽

T.-E. Ciuleanu ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Carcinoma ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70127-0 ◽

2015 ◽

Vol 16 (5) ◽

pp. 499-508 ◽

Cited By ~ 406

Author(s):

Josep Tabernero ◽

Takayuki Yoshino ◽

Allen Lee Cohn ◽

Radka Obermannova ◽

Gyorgy Bodoky ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Preliminary results of a phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line therapy: IMPACT study.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14114 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14114-e14114

Author(s):

M. Schmidt ◽

H. Schmoll ◽

F. Mayer ◽

J. Riera ◽

G. Hapke ◽

...

Keyword(s):

Clinical Study ◽

Colorectal Carcinoma ◽

Disease Control ◽

Phase Ii ◽

Impact Study ◽

First Line ◽

Preliminary Results ◽

First Line Therapy ◽

Line Therapy ◽

Advanced Colorectal Carcinoma

1904: Outcomes of Large Renal Calculi (>2-Cm) Treated with ESWL as First Line Therapy

The Journal of Urology ◽

10.1016/s0022-5347(18)39096-7 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 503-503

Author(s):

Richard Vanlangendock ◽

Ramakrishna Venkatesh ◽

Jamil Rehman ◽

Chandra P. Sundaram ◽

Jaime Landman

Keyword(s):

Renal Calculi ◽

First Line ◽

First Line Therapy ◽

Superselective Catheterization and Embolization as First-Line Therapy for Lower Gastrointestinal Bleeding

Yearbook of Diagnostic Radiology ◽

10.1016/s0098-1672(08)70416-8 ◽

2006 ◽

Vol 2006 ◽

pp. 253-255

Author(s):

G.A. Gardiner

Keyword(s):

Gastrointestinal Bleeding ◽

Lower Gastrointestinal Bleeding ◽

First Line ◽

Superselective Catheterization ◽

First Line Therapy ◽

Author response for "Prognostic significance of infectious episodes occurring during first-line therapy for diffuse large B-cell lymphoma - A nationwide cohort study"

10.1002/hon.2734/v2/response1 ◽

2020 ◽

Author(s):

Michael Roost Clausen ◽

Sinna Pilgaard Ulrichsen ◽

Maja Bech Juul ◽

Christian B. Poulsen ◽

Brian Østergaard ◽

...

Keyword(s):

Cohort Study ◽

B Cell ◽

Cell Lymphoma ◽

Prognostic Significance ◽

B Cell Lymphoma ◽

First Line ◽

First Line Therapy ◽

Large B Cell Lymphoma ◽

Line Therapy ◽

Large B Cell